| PRODUCTSSERVICESCOMPANYCONTACTFAQ |
|
Description: structure given in first source
Also Known As:| 1. | Hemolysis
08/01/1991
- "Hematologic monitoring for evidence of intravascular hemolysis should be included in future studies with 773U82.HCl."
08/01/1991 - "The dose-limiting toxicity of 773U82.HCl was hemolysis noted at 980 mg/m2" Order ALL the reference details at left... |
| 2. | Pancreatic Neoplasms (Pancreatic Cancer)
01/01/1994
- "773U82 mesylate is not active in pancreatic cancer."
01/01/1994 - "Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer." Order ALL the reference details at left... |
| 3. | Neoplasms (Cancer)
08/01/1991
- "Significant antitumor activity for 773U82.HCl was documented in a variety of murine and human tumor models"
Order ALL the reference details at left... |
CureHunter Patient-Physician Summary Reports collect in one document all the
medications ever reported in the US National Library of Medicine—1949 to the present—to
be effective against your target disease.
CureHunter research summary reports will vary in length from 25 to 250 pages.
Analytic charts allow you and your physicians to see at a glance your
medication options—including new, promising, off-label and experimental
all rated for clinical efficacy.
| Price: | $24.00
& Delivery via
PDF download
updates for 1 year |
| Price: | $490.00
access via web interface 1 year subscription |
| Price: | $45.00
access via "curehunter.com/m" 1 year subscription |